Scholars Central

Conference abstractPublished 5 Sep 2011

Novel therapeutic strategies in virology: Cancer terminator viruses and innovative delivery approaches

Authors: Paul B. Fisher

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Although in principle, genetically engineered viruses, particularly type 5 adenoviruses (Ad5), hold signifi cant promise as therapeutics, this potential has not been realized. Several factors contribute to lack of clinical translation. Systemic administration of Ad5 results in sequestration in the liver and neutralization by the immune system. Additionally, replication competence is not suffi cient to elicit objective clinical responses. We have created improved therapeutic viruses and approaches to circumvent liver entrapment and immune recognition. Using the promoter region of progression elevated gene-3 (PEG-Prom), which displays cancerspecifi c expression, we have developed conditionally replication competent adenoviruses that selectively replicate in cancer cells. To enhance the effi cacy of these viruses as therapeutics, we engineered the cancer-specifi c apoptosisinducing cytokine gene melanoma diff erentiation associated gene-7/Interleukin-24 (mda-7/IL-24) in these adenoviruses. Th ese novel Cancer Terminator Viruses (CTV) have potent ?bystander? activity and selectively kill both primary and distant cancers in animal models of human cancer. Since Ad5 enters cells through Coxsackie Adenovirus Receptors (CAR), and these receptors are frequently reduced in primary human cancers limiting infection, we created a tropism-modifi ed serotype 5 and serotype 3 chimeric CTV (Ad.5/3-CTV) with enhanced infectivity and anti-cancer activity in CAR-defi cient cancer cells, while retaining activity in CAR positive cells, thereby increasing its potential applications for cancer therapy. To avoid liver trapping and immune clearance, and to provide target-specifi c delivery, we developed a stealth approach for delivering the CTV by microbubbles combined with ultrasound to release the viruses in the tumor milieu. Th is approach is paradigm shift ing and off ers potential for enhancing systemic cancer therapy using viruses.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Antivirals & Antiretrovirals
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Paul B. Fisher”